FealtySign in

UNIVERSAL HEALTH SERVICES INC

(UHS)

CIK 352915 · SEC filings only

Not gradedDividend record
shown as history
company entity
18 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

18 declarations · 0 raised · 15 held · 0 cut · held 15 quarters

  1. NOTED$0.2000/shperiod ended 2019-09-30Filing ↗
  2. HELD$0.1000/shperiod ended 2019-06-30Filing ↗
  3. HELD$0.1000/shperiod ended 2019-03-31Filing ↗
  4. HELD$0.1000/shperiod ended 2018-09-30Filing ↗
  5. HELD$0.1000/shperiod ended 2018-06-30Filing ↗
  6. HELD$0.1000/shperiod ended 2018-03-31Filing ↗
  7. HELD$0.1000/shperiod ended 2017-09-30Filing ↗
  8. HELD$0.1000/shperiod ended 2017-06-30Filing ↗
  9. HELD$0.1000/shperiod ended 2017-03-31Filing ↗
  10. HELD$0.1000/shperiod ended 2016-09-30Filing ↗
  11. HELD$0.1000/shperiod ended 2016-06-30Filing ↗
  12. HELD$0.1000/shperiod ended 2016-03-31Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
0 resolved promises

Not enough resolved promises to grade

0 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Pro

buyback history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (11)

Open · buyback authorization

Pursuant to our $2.7 billion stock repurchase program, which had an aggregate available repurchase authorization of $559.6 million as of March 31, 2021

unresolved — no outcome on file$559.6Mreceipt →
Open · buyback authorization

our Board of Directors authorized a $1.0 billion increase to our stock repurchase program, which increased the aggregate authorization to $3.7 billion

unresolved — no outcome on file$3.7000receipt →
Open · buyback authorization

we had an aggregate stock repurchase authorization of $3.7 billion

unresolved — no outcome on file$3.7000receipt →
Open · buyback authorization

our Board of Directors authorized a $1.4 billion increase to our stock repurchase program

unresolved — no outcome on file$1.4000receipt →
Open · buyback authorization

our Board of Directors authorized a $1.4 billion increase to our stock repurchase program

unresolved — no outcome on file$1.40Breceipt →
Open · buyback authorization

As of September 30, 2023, we had an aggregate available repurchase authorization of approximately $580 million.

unresolved — no outcome on file$580.0000receipt →
Open · buyback authorization

As of March 31, 2024, we had an aggregate available repurchase authorization of approximately $298 million.

unresolved — no outcome on file$298.0000receipt →
Open · buyback authorization

our Board of Directors authorized a $1.0 billion increase to our stock repurchase program

next filing due$1.0000receipt →
Open · buyback authorization

our Board of Directors authorized a $1.0 billion increase to our stock repurchase program

resolves in ~45 days$1.00Breceipt →
Open · buyback authorization

As of December 31, 2024, we had an aggregate available repurchase authorization of approximately $824.4 million pursuant to our stock repurchase program.

resolves in ~170 days$824.4000receipt →
Open · buyback authorization

our Board of Directors authorized a $1.5 billion increase to our stock repurchase program

resolves in ~413 days$1.5000receipt →
0 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
B+Guidance record
grade
company entity
6 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (13)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Jul 28, 2026
    Adjusted EPS – diluted $22.28 per share $23.65 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Feb 26, 2026
    EPS-diluted $22.64 per share $24.52 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Oct 28, 2025
    Adjusted EPS – diluted $21.50 per share $22.10 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Jul 29, 2025
    Our revised 2025 forecasted Adjusted EPS-diluted is estimated to be $20.00 per share to $21.00 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Feb 27, 2025
    EPS-diluted $18.45 per share $19.95 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Jul 25, 2024
    Our revised 2024 forecasted Adjusted EPS-diluted is estimated to be $15.40 per share to $16.20 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Feb 27, 2024
    Our EPS-diluted range is estimated to be $13.00 per diluted share to $14.00 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Jul 26, 2023
    Adjusted EPS – diluted $9.85 per share $10.50 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Feb 27, 2023
    Our Adjusted EPS-diluted range is estimated to be $9.50 per diluted share to $10.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Feb 24, 2022
    Our Adjusted EPS-diluted range is estimated to be $11.90 per diluted share to $12.90 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Jul 27, 2021
    Our revised 2021 forecasted Adjusted EPS-diluted is estimated to be $11.46 per share to $12.16 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Feb 25, 2021
    Our Adjusted EPS-diluted range is estimated to be $10.05 per diluted share to $11.05 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Feb 27, 2019
    Adjusted EPS-diluted $9.70 per share $10.40 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (1) · 6 superseded

Open · revenue guidance fy

Net revenues $18.501 billion $18.762 billion

resolves in ~202 daysreceipt →
Superseded · revenue guidance fy

Net revenues $18.417 billion $18.789 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Our net revenues are estimated to be approximately $14.044 billion to $14.314 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Our net revenues are estimated to be approximately $15.411 billion to $15.706 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Our 2025 forecasted range of net income attributable to UHS, and EPS-diluted, exclude certain items as described below because we do not believe we can forecast those items with sufficient accuracy. Adjusted EBITDA net of NCI, is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of our operating performance. Please see the Supplemental Non-GAAP Disclosures - 2025 Operating Results Forecast schedule as included herein for additional information and a reconciliation of our 2025 forecasted range of net income attributable to UHS to our 2025 forecasted range of Adjusted EBITDA net of NCI.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Our revised 2025 forecasted net revenues are estimated to be approximately $17.096 billion to $17.312 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Our net revenues are estimated to be approximately $12.125 billion to $12.361 billion

revised by a later guidancereceipt →

Credibility timeline

BEAT · Feb 26, 2020BEAT · Feb 24, 2022MISSED · Feb 27, 2023KEPT · Feb 27, 2024BEAT · Feb 26, 2025KEPT · Feb 25, 2026
20202026
Timeline as a list
  • Feb 26, 2020BEATNet revenues $11.213 billion $11.361 billion
  • Feb 24, 2022BEATOur revised 2021 forecasted net revenues are estimated to be approximately $12.351 billion to $12.502 billion
  • Feb 27, 2023MISSEDOur net revenues are estimated to be approximately $13.424 billion to $13.694 billion
  • Feb 27, 2024KEPTNet revenues $14.130 billion $14.330 billion
  • Feb 26, 2025BEATOur revised 2024 forecasted net revenues are estimated to be approximately $15.565 billion to $15.753 billion
  • Feb 25, 2026KEPTNet revenues $17.306 billion $17.445 billion
6 resolved guidance promises · 13dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →